Taking into consideration the importance of MAPK in CML, specific inhibitors for BCR-ABL tyrosine kinase activity have been designed and are being developed for treating CML [15]. This evidence concerns the gene BCR and chronic myelogenous leukemia, BCR-ABL1 positive.